Development, characterization, and in vitro–in vivo evaluation of polymeric nanoparticles containing miconazole and farnesol for treatment of vulvovaginal candidiasis

Página do item simplificado
dc.creatorCosta, Adelaide Fernandes
dc.creatorAraújo, Deize Evangelista
dc.creatorCabral, Mirlane dos Santos
dc.creatorBrito, Isabella Teles
dc.creatorMenezes, Liliana Borges de
dc.creatorPereira, Maristela
dc.creatorAmaral, Andre Correa
dc.date.accessioned2025-03-06T12:22:03Z
dc.date.available2025-03-06T12:22:03Z
dc.date.issued2019
dc.description.abstractVulvovaginal candidiasis (VVC) is caused mainly by the opportunistic fungus Candida albicans, and its yeast to hyphae transition is considered a major virulence factor. Farnesol is a molecule that inhibits yeast to hyphae transition. The increased incidence of VVC has influenced a need for developing new therapeutic strategies. The objective was to develop a mucoadhesive nanostructured system composed of miconazole and farnesol co-encapsulated within chitosan nanoparticles. The miconazole presented a minimal inhibitory concentration (MIC) of 1 μg/ml against C. albicans. The farnesol was capable of inhibiting yeast to hyphae transition at levels greater or equal to 300 μM. The combination of miconazole and farnesol showed no change in miconazole MIC. Chitosan nanoparticles containing miconazole and farnesol were prepared by ionic gelation and showed favorable characteristics for use on mucous membranes. They showed size variation and polydispersion index (PDI) after 30 days, but the efficiency of drug encapsulation was maintained. Regarding toxicity in cultured fibroblasts (BALB/c 3T3) the nanoparticles were considered nontoxic. The nanoparticles showed antifungal activity against the C. albicans strain used with MICs of 2.5 μg/ml and 2 μg/ml for nanoparticles containing miconazole or miconazole/farnesol, respectively. Nanoparticles containing farnesol inhibited yeast to hyphae transition at concentrations greater than or equal to 240 μM. The in vivo antifungal activity was assessed in the murine model for VVC. The results suggested that chitosan nanoparticles containing miconazole and farnesol were effective at inhibiting fungal proliferation. Additionally, chitosan nanoparticles containing farnesol were capable of decreasing the pathogenicity of infection, demonstrated through the absence of inflammation.
dc.identifier.citationCOSTA, Adelaide Fernandes et al. Development, characterization, and in vitro-in vivo evaluation of polymeric nanoparticles containing miconazole and farnesol for treatment of vulvovaginal candidiasis. Medical Mycology, Oxford, v. 57, n. 1, p. 52-62, 2019. DOI: 10.1093/mmy/myx155. Disponível em: https://academic.oup.com/mmy/article/57/1/52/4817017?login=true. Acesso em: 28 fev. 2025.
dc.identifier.doi10.1093/mmy/myx155
dc.identifier.issn1369-3786
dc.identifier.issne- 1460-2709
dc.identifier.urihttps://academic.oup.com/mmy/article/57/1/52/4817017?login=true
dc.language.isoeng
dc.publisher.countryGra-bretanha
dc.publisher.departmentInstituto de Ciências Biológicas - ICB (RMG)
dc.rightsAcesso Restrito
dc.subjectCandidiasis
dc.subjectFarnesol
dc.subjectMiconazole
dc.subjectNanoparticles
dc.subjectAntifungal
dc.titleDevelopment, characterization, and in vitro–in vivo evaluation of polymeric nanoparticles containing miconazole and farnesol for treatment of vulvovaginal candidiasis
dc.typeArtigo

Arquivos

Licença do Pacote
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Baixar

Coleções

ICB - Artigos publicados em periódicos